home.aspx

 
.

STREAMLINING DRUG DISCOVERY ASSAYS FOR CANCER AND CARDIOVASCULAR DISEASE

SHARESHARESHARE
Declining R&D productivity is a key challenge in the pharmaceutical industry today. To increase the success rate of candidate drugs entering the clinical phase, companies must address the early stages of drug discovery. In lead optimization, target-based assays are still the most affordable means of rapidly performing fast iterations and remain core to screening. However, the desire for biological-relevance is driving ongoing growth in cell-based assays. Meanwhile, screeners are continuing to streamline processes by eliminating time-consuming steps such as washing, by generating multiple readouts simultaneously from a single well, or by using automation.